Acquired Company

AlloVir completed its merger with Kalaris Therapeutics on 3/18/2025, and the combined company will trade on Nasdaq under the ticker KLRS.

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more

628 Middlefield Road, Palo Alto, CA, 94301, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

201.4M

52 Wk Range

$2.14 - $12.90

Previous Close

$10.77

Open

$10.67

Volume

43,779

Day Range

$10.62 - $11.22

Enterprise Value

139.9M

Cash

77.0M

Avg Qtr Burn

-11.33M

Insider Ownership

12.61%

Institutional Own.

96.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TH103 Details Neovascular Age-Related Macular Degeneration (nAMD)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.